@article{569451efbe214832a99e3ba9031120b0,
title = "Use of rituximab for the treatment of rheumatoid arthritis: The Latin American context",
keywords = "Anti-CD20 antibody, Biologic therapy, Latin America, Rheumatoid arthritis, Rituximab, Treatment guidelines",
author = "Soriano, {E. R.} and Claudio Galarza-Maldonado and Cardiel, {M. H.} and Pons-Estel, {B. A.} and L. Massardo and Caballero-Uribe, {C. V.} and Achurra-Castillo, {A. F.} and Barile-Fabris, {L. A.} and J. Ch{\'a}vez-Corrales and D{\'i}az-Coto, {J. F.} and Esteva-Spinetti, {M. H.} and M. Guibert-Toledano and Palazuelos, {Irazoque F.} and Keiserman, {M. W.} and Lomonte, {A. V.} and Mota, {L. M.H.} and {Pineda Villase{\~n}or}, C. and Alarc{\'o}n, {G. S.}",
note = "Funding Information: Disclosure statement: E.R.S. has received grants from Abbott and support to attend ACR from Wyeth. M.H.C. has conducted clinical trials with rituximab as a principal investigator. L.M.H.M. has been a co-investigator in rituximab clinical trials for Roche and has received financial support for Medical Congress from Roche. C.G.-M. has been a principle investigator in biologic products clinical trials for Roche and Abbott. He has also received honoraria as an Advisory Board member for Wyeth. All other authors have declared no conflicts of interest. Funding Information: Funding: The conceptualization of this consensus paper was made possible by an unrestricted grant from Roche.",
year = "2008",
month = jul,
doi = "10.1093/rheumatology/ken015a",
language = "English",
volume = "47",
pages = "1097--1099",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "7",
}